KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Investing Activities (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Cash from Investing Activities for 15 consecutive years, with -$51.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 306.0% to -$51.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 102.16% increase, with the full-year FY2025 number at $4.1 million, up 102.16% from a year prior.
  • Cash from Investing Activities was -$51.3 million for Q4 2025 at Supernus Pharmaceuticals, down from $48.7 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $239.8 million in Q1 2023 to a low of -$82.2 million in Q3 2022.
  • A 5-year average of -$10.8 million and a median of -$39.6 million in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 1341.65% in 2022, then surged 484.57% in 2023.
  • Supernus Pharmaceuticals' Cash from Investing Activities stood at $76.1 million in 2021, then crashed by 164.05% to -$48.8 million in 2022, then plummeted by 35.3% to -$66.0 million in 2023, then skyrocketed by 80.85% to -$12.6 million in 2024, then tumbled by 306.0% to -$51.3 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Cash from Investing Activities are -$51.3 million (Q4 2025), $48.7 million (Q3 2025), and -$30.6 million (Q2 2025).